Taiwan:6540.TW

JHL Biotech's Final Trading Day on Taipei Exchange

HSINCHU and WUHAN, China, Feb. 12, 2018 /PRNewswire/ -- JHL Biotech , Inc. (TPEx: 6540) announces that today,Monday, February 12, 2018, is the final day for trading of JHL shares on the Emerging Stock Market of the Taipei Exchange ("TPEx")....

2018-02-12 08:00 1671

JHL Biotech Welcomes New Chief Medical Officer, Rong Chen

HSINCHU and WUHAN, China, Jan. 2, 2018 /PRNewswire/ -- JHL Biotech announced that Rong Chen has been appointed Chief Medical Officer effectiveJanuary 1. As CMO, Dr. Chen will oversee JHL's medical and clinical development work as part of its mission to make world-clas...

2018-01-02 06:55 1868

JHL Biotech Receives Approval From European Authorities to Begin Biosimilar Clinical Trial

HSINCHU, , Feb. 15, 2016 /PRNewswire/ -- JHL Biotech, Inc. (Stock Code: 6540.TWO) announced it has received authorization from theUnited Kingdom's Medicines and Healthcare Products Regulatory Agency (MHRA) to begin clinical trial for JHL1101, a rituximab biosimilar developed and manufactured ...

2016-02-15 08:00 3705